NCT02213107 2024-11-13
Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.
University of Rochester
Phase 2 Completed
Clinical Trials
11 trialsNCT00668642 2023-08-22
Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer
Endeavor Health
Phase 2 Completed
NCT01547299 2018-10-23
Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer
Pfizer
Phase 2 Completed
NCT00298155 2018-08-09
TAPS
University of Washington
Phase 2 Completed
NCT01393730 2018-03-15
Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00470834 2017-02-27
Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy
GlaxoSmithKline
Phase 4 Completed
NCT00363311 2017-01-18
Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men
GlaxoSmithKline
Phase 4 Completed
NCT00056407 2016-09-23
REDUCE
GlaxoSmithKline
Phase 3 Completed
NCT00673127 2015-04-22
KHAD
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00706966 2014-01-17
MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer
University of California, San Francisco
Phase NA Completed
NCT00558363 2012-03-21
ARTS
GlaxoSmithKline
Phase 2 Completed